EMPAVELI (Swedish Orphan Biovitrum Pty Ltd)
Product name
EMPAVELI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
83 (255 working days)
Active ingredients
pegcetacoplan
Registration type
EOI
Indication
EMPAVELI is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH).